← Back to Search

Alkylating agent

Combination Chemotherapy for Nasopharyngeal Cancer

Phase 2

Waitlist Available

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Metastatic disease must be limited to site amenable to curative irradiation or surgical resection

Performance status: ECOG 0-2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well giving a combination of drugs works in treating patients with nasopharyngeal cancer.

Who is the study for?

This trial is for people with stage IIB, III, or IV nasopharyngeal cancer who haven't had chemotherapy or radiotherapy for it. They should be in good health otherwise, not have other cancers (except some skin cancers or cervical carcinoma in situ), and must be able to handle a significant amount of IV fluids daily. Pregnant women can't join, and those who can have children must use birth control.Check my eligibility

What is being tested?

The study is testing how well different combinations of chemotherapy drugs work together to treat advanced nasopharyngeal cancer. It's a Phase II trial which means they're looking at the effectiveness while monitoring side effects.See study design

What are the potential side effects?

Chemotherapy may cause fatigue, nausea, vomiting, hair loss, increased risk of infection due to low blood cell counts, mouth sores and potential damage to organs like the heart or liver depending on specific drugs used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer has spread, but it can still be removed or treated with radiation.

Select...

I am able to get out of my bed or chair and move around.

Select...

I have never had head or neck cancer, or if I did, it was only treated with surgery.

Select...

I do not have serious heart disease.

Select...

I do not have severe numbness or pain in my hands or feet.

Select...

I do not have any serious illnesses besides my current condition.

Select...

I haven't had any cancer in the past 3 years, except for minor skin cancer or early-stage cervical cancer.

Select...

I can safely receive 3-4 liters of IV fluids daily.

Select...

My nasopharynx cancer is at stage IIB, III, or IV and has not been treated before.

Select...

My cancer came back in the same area after surgery.

Select...

My kidney function is normal, with creatinine levels at or below 1.5 mg/dL or clearance above 50 mL/min.

Select...

My lungs are healthy without major diseases.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 12Eligibility criteria met

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor

1,078 Previous Clinical Trials

340,872 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,153 Total Patients Enrolled

A. Dimitrios Colevas, MDStudy ChairNCI - Investigational Drug Branch

5 Previous Clinical Trials

73 Total Patients Enrolled

Media Library

Cisplatin (Alkylating agent) Clinical Trial Eligibility Overview. Trial Name: NCT00004164 — Phase 2

Head and Neck Cancers Research Study Groups:

Head and Neck Cancers Clinical Trial 2023: Cisplatin Highlights & Side Effects. Trial Name: NCT00004164 — Phase 2

Cisplatin (Alkylating agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004164 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrolment currently open for this trial?

"Contrary to what is documented on clinicaltrials.gov, this particular trial has ceased enrolling patients. Originally posted in 1999 and last edited in 2009, the study no longer requires participants; however, 480 other studies are looking for volunteers at this time."

Answered by AI

Does this remedy have the endorsement of the Food and Drug Administration?

"Based on our assessment at Power, this particular treatment has been rated a 2 due to the limited data available in Phase 2 trials that demonstrates its safety but not efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx

1999. "Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00004164.

All > Head And Neck Cancer